The Institute for Clinical and Economic Review (ICER) on Wednesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for chronic or episodic migraine. Therapies reviewed include erenumab (Amgen/Novartis), fremanezumab (Teva), and galcanezumab (Eli Lilly). Findings contained in this report are preliminary and subject to change based on additional stakeholder input and further analysis of data.
ICER is committed to engaging with all stakeholders in a thorough and transparent manner.
Prior to conducting this review, ICER spoke with key patient groups, clinical experts, and manufacturers, and accepted public comments on a Draft Scoping Document.
The current draft report incorporates input received from patients, clinicians, and other stakeholders during each of these opportunities for engagement.
The Draft Evidence Report and Draft Voting Questions are open to public comment until 5 p.m. EST May 8. All stakeholders are invited to submit formal comments by email to publiccomments@icer-review.org.
To read the full press release on ICER’s website, click here.
